The Searle Company Limited: Searle Subsidiary Partners with MDM and Atco
Summary
Nextar Pharma partners with MDM and Atco for manufacturing agreements, enhancing future profitability.
Kind of disclosure: Partnership/JV
Read the original filingKey facts
- Partnership with Martin Dow Marker Limited
- In-principle agreement
- Potential partnership with Atco Laboratories Limited
- Terms pending finalization
- Disclosure compliance with SECP
- Sections 96 and 131 of Securities Act, 2015
- Disclosure dated June 11, 2026
- Material information announcement
- Finalization of terms pending
- Risk factor
The Searle Company Limited (SEARL) on Nafa
Last price Rs 79.56 · Pharmaceuticals · You can own SEARL shares from your phone.
More SEARL announcements
- Material informationSearle Appoints New Chairman and CEOThe Searle Company Limited announces the appointment of Mr. Munis Abdullah as Chairman and re-appointment of Mr. Tahir Ahmed as CEO.
- NoticeSHORT NOTICE (EMERGENT) BOARD MEETING- OTHER THAN FINANCIAL RESULTS
- NoticeCredit of final cash dividend
- NoticeTransmission of Quarterly Financial Statements for the Period Ended 30/09/2026
- NoticeCERTIFIED TRUE COPY OF THE RESOLUTIONS PASSED AT THE 61ST ANNUAL GENERAL MEETING OF THE SEARLE COMPANY LIMITED
- Financial resultThe Searle Company Limited reported a net profit of Rs 1.20 billion for the quarter ended September 30, 2026Filed as: Financial Results for the Quarter Ended 2026-09-30
Source: The Searle Company Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.